2023
AGM Chairman’s Address and Investor Presentation
22/11/2023US Medicare confirms reimbursement price for PromarkerD
09/11/2023Proteomics International receives $1.85 million in R&D tax incentive
30/10/2023Investor Presentation – Non-deal Roadshow
26/10/2023Quarterly Activities Report September 2023 – Appendix 4C
23/10/2023Notice of Annual General Meeting 2023
02/10/2023Webinar and Q&A on PromarkerD US CMS price & TGA decision
29/09/2023PromarkerD US CMS price & TGA decision
08/09/2023Oseophageal cancer test presented
04/09/2023OxiDx technology secures Japan patent
22/08/2023Corporate Governance Statement and Appendix 4G
22/08/2023Annual Report 2023 to shareholders
22/08/2023Preliminary Final Report
14/08/2023Exercise of Options
14/08/2023Application for quotation of securities – PIQ
25/07/2023Proteomics presents at 17th Bioshares Biotech Summit
24/07/2023Quarterly Activities Report and Year Ahead
20/07/2023Promarker pipeline – Oesophageal cancer diagnostic test update
10/05/2023Proteomics International & Sonic Healthcare USA sign exclusive licence agreement to market PromarkerD in the US
05/05/2023New diagnostic blood test showcased at world’s premier endometriosis conference
03/05/2023PromarkerD is a potential diagnostic tool to demonstrate the benefits of canagliflozin in diabetic kidney disease
27/04/2023Quarterly update March 2023 – Appendix 4C
26/04/2023Clinical Advisory Board expanded to support PromarkerD USA and global rollout
17/04/2023Proteomics renews its ISO 13485 certification & ISO 17025 accreditation
24/03/2023Results of a novel blood test for Endometriosis were presented at international conference
01/03/2023US update: PromarkerD licensing negotiations
15/02/2023Distribution agreement for PromarkerD in Britain extended
02/02/2023Investor Presentation – Euroz Hartleys Healthcare Forum
31/01/2023Letter of intent with Sonic Healthcare USA extended
31/01/2023Quarterly Update December 2022 – Appendix 4C
09/01/2023Letter of intent with Sonic Healthcare USA extended
03/01/2023CPT PLA Reimbursement Code Approved in US for PromarkerD
